1:40 PM
 | 
Nov 06, 2018
 |  BC Extra  |  Clinical News

Mallinckrodt Niemann-Pick disease therapy fails pivotal trial

Mallinckrodt plc (NYSE:MNK) said VTS-270 showed no significant separation from placebo in a Phase IIb/III trial to treat Niemann-Pick disease type C1 (NPC1). Mallinckrodt CSO and EVP Steven Romano disclosed the result on a conference call Tuesday to discuss the company's 3Q18 earnings.

The double-blind, international trial...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >